Cargando…

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

BACKGROUND: Angiogenesis is essential for the progression and metastatic spread of solid tumours. Expression of vascular endothelial growth factor (VEGF) has been linked to poor survival among osteosarcoma patients but the clinical relevance of monitoring blood and urine angiogenic factors is uncert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabone, Marie-Dominique, Brugières, Laurence, Piperno-Neumann, Sophie, Selva, Marie-Ange, Marec-Bérard, Perrine, Pacquement, Hélène, Lervat, Cyril, Corradini, Nadège, Gentet, Jean-Claude, Couderc, Rémy, Chevance, Aurélie, Mahier-Ait Oukhatar, Céline, Entz-Werle, Natacha, Blay, Jean-Yves, Le Deley, Marie-Cecile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473001/ https://www.ncbi.nlm.nih.gov/pubmed/28619014 http://dx.doi.org/10.1186/s12885-017-3409-z

Ejemplares similares

High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group
por: Marec-Berard, Perrine, et al.
Publicado: (2014)

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
por: Penel-Page, Mathilde, et al.
Publicado: (2015)

Bone Sarcomas: From Biology to Targeted Therapies
por: Gaspar, Nathalie, et al.
Publicado: (2012)

Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France
por: Corvest, Victoria, et al.
Publicado: (2022)

Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
por: Thebault, Eric, et al.
Publicado: (2021)

Ewing’s Sarcoma of the Head and Neck: Margins are not just for surgeons
por: Bouaoud, Jebrane, et al.
Publicado: (2018)

Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases
por: Guillon, Maud AM, et al.
Publicado: (2011)

Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?
por: Gomez-Brouchet, Anne, et al.
Publicado: (2021)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
por: Broudic-Guibert, Morgane, et al.
Publicado: (2019)

Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping
por: Entz-Werle, N, et al.
Publicado: (2003)

High-dose chemotherapy followed by whole lung irradiation in pulmonary relapse Ewing’s sarcomas: a retrospective multicenter study
por: Duverge, Loig, et al.
Publicado: (2022)

Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial
por: Verschuur, Arnauld, et al.
Publicado: (2018)

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Association between genetic polymorphisms and platinum-induced ototoxicity in children
por: Lui, Gabrielle, et al.
Publicado: (2018)

Desmoplastic Small Round Cell Tumor: Current Management and Recent Findings
por: Dufresne, Armelle, et al.
Publicado: (2012)

Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
por: Penel, Nicolas, et al.
Publicado: (2020)

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
por: Brard, Caroline, et al.
Publicado: (2019)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Solitary Fibrous Tumors and So-Called Hemangiopericytoma
por: Penel, Nicolas, et al.
Publicado: (2012)

Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
por: Leblond, Pierre, et al.
Publicado: (2023)

Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE)
por: de Tersant, Marie, et al.
Publicado: (2020)

Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP
por: Supiot, Stéphane, et al.
Publicado: (2018)

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
por: Nguyen, Aurelia, et al.
Publicado: (2013)

Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas
por: Pinto, Lia, et al.
Publicado: (2021)

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
por: Sabo, Amelia-Naomi, et al.
Publicado: (2021)

Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
por: Kubicek, Pierre, et al.
Publicado: (2023)

Percutaneous Core Needle Biopsy Can Efficiently and Safely Diagnose Most Primary Bone Tumors
por: Crenn, Vincent, et al.
Publicado: (2021)

HGG-34. A DNA DAMAGE REPAIR SIGNATURE IN PRIMARY AND RECURRENT PEDIATRIC HIGH-GRADE GLIOMAS: PROGNOSTIC AND THERAPEUTIC VALUE
por: Entz-Werle, Natacha, et al.
Publicado: (2021)

EPCT-11. PHASE 1 STUDY OF FLUVASTATIN-CELECOXIB COMBINATION IN CHILDREN WITH RELAPSING/REFRACTORY OPTICO-CHIASMATIC LOW-GRADE GLIOMA OR HIGH-GRADE GLIOMAS (FLUVABREX): FINAL RESULTS
por: Andrew, Nicolas, et al.
Publicado: (2020)

HGG-36. HIF-2: A NEW DRUG TARGET IN PEDIATRIC HIGH-GRADE GLIOMA WITH PROMISING PRECLINICAL RESULTS
por: Fuchs, Quentin, et al.
Publicado: (2020)

Glioblastoma Metabolism: Insights and Therapeutic Strategies
por: Bernhard, Chloé, et al.
Publicado: (2023)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
por: Jobard, Elodie, et al.
Publicado: (2017)

Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)(☆)
por: Gaspar, N., et al.
Publicado: (2021)

Thymus and Mediastinal Node Involvement in Childhood Langerhans Cell Histiocytosis: Long-Term Follow-Up From the French National Cohort
por: Ducassou, Stephane, et al.
Publicado: (2013)

DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
por: Geyer, Lucas, et al.
Publicado: (2023)

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances
por: Geyer, Lucas, et al.
Publicado: (2023)

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
por: Jannier, Sarah, et al.
Publicado: (2020)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltn9v4fmspggbdg9q4q83jm4tc